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Jun-ichi Oyama1*, Yukihito Higashi2 and Koichi Node1Abstract
An impaired endothelial function has been recognized in the early stage of atherosclerosis, and is a major factor
affecting the future development of cardiovascular events. Type 2 diabetes mellitus (T2DM) is widely prevalent, and
is one of the most important risk factors for cardiovascular disease. T2DM is associated with increases in both
morbidity and mortality, particularly from cardiovascular disease.
New therapies based on the incretin hormone and its actions are now becoming widely used, and appear to offer
advantages over conventional therapies by keeping the body weight steady and limiting hypoglycemia, while also
achieving attractive glycemic control. However, there is little data available about the effects of incretins on the
cardiovascular system.
This review will focus on the effects of incretin therapies, including glucagon-like peptide-1 (GLP-1) analogs and
dipeptidyl peptidase (DPP)-4 inhibitors, on the endothelial function, and will discuss the potential mechanisms
underlying these effects.
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Type 2 diabetes (T2DM) is one of the most important
risk factors for the development of cardiovascular dis-
ease (CVD) because it promotes systemic atherosclerosis
and lifestyle-associated diseases. Recently, increasing evi-
dence has revealed that impaired endothelial function
leads to future cardiovascular events, including those in
patients with T2DM. Endothelial dysfunction is an early
feature of atherosclerosis that is characterized by a re-
duction of the bioavailability of vasodilators, particularly
nitric oxide (NO) [1]. This condition is seen in various
clinical populations, including patients with T2DM. The
measurement of endothelial function as indicated by the
flow-mediated dilation (FMD) via ultrasound has been
established as a reliable non-invasive measurement of
the endothelial function [2] and has been shown to cor-
relate with the findings of more invasive testing of the
endothelial function [3]. Numerous interventions that
improve cardiovascular risk factors and reduce cardio-
vascular morbidity and mortality have been shown to in-
crease the brachial artery reactivity measured by FMD,
thus improving the endothelial function [4].* Correspondence: junoyama@cc.saga-u.ac.jp
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stated.Incretin hormones depend on the level of blood glu-
cose to stimulate insulin. Recently, increasing evidence
has suggested that glucagon-like peptide-1 (GLP-1)-re-
lated therapy has potent pleiotropic benefits on cardio-
vascular risk factors, beyondthe glycemic control. This
review focuses on the theoretical and practical effects of
incretin-related therapy on endothelial function, and de-
scribes the possible mechanism(s) of action.Biology of incretin hormones
Incretin hormones are secreted from the gastrointestinal
tract in response to food intake and have several sys-
temic effects, including the glucose-dependent stimula-
tion of insulin secretion by pancreatic beta-cells. Two
incretins have been identified: GLP-1, derived from the
L-cells of the distal small intestine and large bowel, and
glucose-dependent insulinotropic polypeptide (GIP), de-
rived from the K-cells of the proximal small intestine.
GLP-1 and GIP are glucose-lowering agents that can
interfere with postprandial hyperglycemia, which has
been demonstrated to be associated with cardiovascular
complications. GLP-1 is secreted primarily in two forms,
GLP-1-(7–37) and GLP-1-(7–36)NH(2), both of which
bind to a specific GLP-1 receptor (GLP-1R) on the pan-
creatic β-cell and augment glucose-stimulated insulin se-
cretion. These peptides arise from the selective cleavageLtd. This is an Open Access article distributed under the terms of the Creative
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dant in the circulation after meals and stimulates insulin se-
cretion by interacting with GLP-1R on pancreatic β-cells.
Activation of GLP-1R on β-cells leads to rapid increases in
levels of cAMP and intracellular calcium followed by insu-
lin exocytosis in a glucose-dependent manner [5]. GLP-1R,
a G protein–coupled receptor, has been detected in the
nervous system, heart, vascular smooth muscle cells,
endothelial cells, monocytes and macrophages as well
as the gastrointestinal tract [6] (Figure 1).
The enzyme dipeptidyl peptidase (DPP)-4, also known
as adenosine deaminase complexing protein 2, degrades
GLP-1 to inactive GLP-1(9–36), and DPP-4 inhibitors
bind to DPP-4 to prevent the breakdown of GLP-1 and
GIP [7], thus increasing the half-life and bioavailability
of active incretins, and enhancing their physiological ef-
fects. GLP-1(7–36) amide has been widely studied for its
role as an active incretin and is referred to as GLP-1, un-
less otherwise specified. GLP-1(9–36) is thought to be
an inactive metabolite due to its 1,000-fold lower affinity
for GLP-1R and actions as a weak competitive antago-
nist without an incretin activity at pharmacological
doses. However, GLP-1(9–36) may have potent effects
on the cardiovascular system, similar to GLP-1(7–36)
amide (Figure 2). Although it remains controversial, GLP-
1 may undergo multiple steps of enzymatic degradation
by DPP-4 and neutral endopeptidase.
Incretin-related drugs
Nowadays, incretin-based therapies, including GLP-1R
agonists and DPP-4 inhibitors, are becoming widely used
as a new class of anti-diabetic drugs that exhibit diffe-
rent mechanisms of action from the conventional anti-
diabetic drugs (Table 1).
Exenatide, one of the GLP-1R agonists and incretin
mimetics, bears a 50% amino acid homology to humanFigure 1 Pleiotropic effects of GLP-1.GLP-1 and it has a longer half-life in vivo, however, has its
side effects including weight loss, nausea and vomiting.
It must be injected twice daily. Liraglutide, a once-daily
GLP-1 derivative, is also a long-acting GLP-1R agonist that
shares 97% sequence identity to human GLP-1(7–37) and
has a plasma half-life of 13 hours after subcutaneous ad-
ministration in contrast to a short half-life of native GLP-1.
DPP-4 inhibitors are also available with fewer side effects.
ADA/EASD/IDF statement concerning the use of incretin
therapy and pancreatic disease was reported in June, 2013.
The strong relationship between incretin-therapy and pan-
cretitis/pancreatic cancer was not recognized for now,
however, we need to look at carefully.
Since DPP-4 inhibitors are associated with a lower
incidence of hypoglycemia compared to conventional
hypoglycemic drugs, they have been suggested to im-
prove the mortality of patients with T2DM because
they can enforce strict glycemic control without caus-
ing fatal hypoglycemia.
Possible effects of incretins on vessels
Incretin and endothelial cells (in vitro)
GLP-1 was shown to attenuate the tumor necrosis factor-
alpha (TNF-α)-mediated induction of plasminogen ac-
tivator inhibitor-1 expression [8] and inhibited advanced
glycation end product (AGE)-induced upregulation of vas-
cular cell adhesion molecule (VCAM)-1 in cultured human
umbilical vein endothelial cells (HUVEC) [9]. It also upreg-
ulated the activity and protein expression of endothelial
NO synthase (eNOS) in HUVEC through GLP-1R-
dependent (GLP-1 (7–36)-related) and-independent (GLP-
1(9–36)-related) pathways [10]. GLP-1 prevented reactive
oxygen species (ROS)-induced cell senescence through the
activation of protein kinase A in HUVEC [11]. It also de-
creased high glucose-induced ROS production and de-
creased the apoptotic index, as well the levels of NADPH
Figure 2 Beneficial effects of GLP-1 on vascular system.
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PKA activity in cardiac microvascular endothelial cells [12].
In turn, GLP-1 promoted angiogenesis in a dose-
dependent manner, which was decreased by Akt inhibitor
IV, a PKC inhibitor and src inhibitor I in a 3D culture sys-
tem where spherules of HUVEC were embedded in a col-
lagen scaffold [13]. Moreover, GLP-1 restored the oxidized
LDL-induced loss of cell viability in accordance with a sig-
nificant decrease in intracellular NO activity. It suppressed
the lipid peroxidation, restored the activities of endogen-
ous antioxidants and decreased the levels of NO and cell
apoptosis by preventing the upregulation of poly (ADP-ri-
bose) polymerase-1/nitrotyrosine and inducible NO syn-
thase protein in islet microvascular endothelial cells [14].
GLP-1 also improved the proliferation and differentiation
of endothelial progenitor cells by upregulating vascular
endothelial growth factor (VEGF) generation [15]. Exendin-
4, a GLP-1 agonist, stimulated the proliferation of humanTable 1 Features of incretin-related therapy
Administration Clear
GLP-1R agonist Subctaneous
Exenatide Twice a day, once a week Re
Liraglutide Once a day Extra
DPP-4 inhibitor Oral
Sitagliptin Once a day Re
Vildagliptin Twice a day Re
Saxagliptin Once a day Re
Linagliptin Once a day Extra
Anagliptin Twice a day Re
Teneligliptin Once a day Extraren
Alogliptin Once a day Re
*Exenatide once weekly has less side effects of GIT as compared to linagrutide.coronary artery endothelial cells through eNOS-, PKA- and
PI3K/Akt-dependent pathways via the GLP-1 receptor [16].
Exendin-4 also and restored the eNOS-induced ROS
production in response to lipotoxicity and protected
against lipoapoptosis through PKA-PI3K/Akt-eNOS-p38
MAPK-JNK-dependent pathways via a GLP-1 receptor-
dependent mechanism [17]. Liraglutide, another GLP-1
analog, prevented the onset of high glucose-induced endo-
plasmic reticulum stress in HUVEC [18] and inhibited
TNF-α-induced intracellular adhesion molecule (ICAM)-
1 and VCAM-1 expression, and these effects were
dependent on the GLP-1R [19]. Moreover, we also dem-
onstrated that liraglutide attenuated TNF-α-induced ROS
production and increased oxidative stress, and that it in-
creased the expression of anti-oxidant enzymes, including
superoxide dismutase-1 and −2, in HUVEC [20].
As DPP-4 inhibitor maintain the plasma level of active
GLP-1, sitagliptin augments the protective effects of GLP-ance Side effects
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with suppressing the receptor for AGE (RAGE) expression
and the subsequent ROS generation [21]. Alogliptin
induced vascular relaxation via NO and endothelial-
derived hyperpolarizing factor-mediated mechanisms, and
increased the NO production with increased eNOS phos-
phorylation in HUVEC, which was not inhibited by GLP-
1R antagonist, exendin 9–39, although NO inhibition or
endothelial denudation decreased relaxation response.
[22]. Therefore, this relaxation by alogliptin may be me-
diated by GLP-1R-independent mechanisms. Since de-
creasing the oxidative stress results in a restoration of
the eNOS function, all of these phenomena, including
the decreased ROS production and increased eNOS ex-
pression, in addition to the endothelial repair and pro-
motion of angiogenesis, lead to an amelioration of the
endothelial function.
The in vivo or ex vivo endothelial function
Exendin-4 significantly increased the NO level, improved
the endothelium–dependent vasodilatation and reduced
the expression of NF-κB in the aortas isolated from
obese rats. This was demonstrated to occur through the
cAMP or AMPK-eNOS pathways [23]. Exendin-4 also
inhibited the monocyte adhesion and attenuated the for-
mation of atherosclerotic lesions in apolipoprotein E-
deficient (ApoE−/−) mice [24]. Liraglutide improved the
endothelial function via GLP-1R, increased the eNOS
level and reduced the ICAM-1 expression in the aortic
endothelium in mice [19]. Liraglutide also inhibited the
progression of atherosclerotic plaques, and improve the
plaque stability in ApoE−/− mice [25], although the ex-
tent of endothelial vasodilatation induced by acetylcho-
line (ACh) was not changed. Sitagliptin protected the
endothelial function of the renal artery in spontaneously
hypertensive rats, and exenatide ameliorated the endo-
thelial dysfunction in the renal arteries from hyperten-
sive patients in an ex vivo study [26]. On the other hand,
Nathanson et al. reported that the endothelial dysfunction
induced by triglycerides was not restored by exendin-4
treatment in rat conduit arteries ex vivo [27].
Other possible effects of Incretins on the endothelium,
possible effects of incretins on vessels and clinical data
Lowering blood pressure
In recent studies, DPP-4 inhibitors and GLP-1 analogs
were recognized to lower the systemic blood pressure
[28,29]. One of the possible mechanisms underlying this
effect is explained by the extraction of Na+, because GLP-
1 induces natriuresis in humans [30]. Another possibility
is the increase in the activity of eNOS described above, be-
cause eNOS-knockout mice [31] and the administration
of a NOS inhibitor both led to increased blood pressure
[32]. Moreover, Kim et al. reported that GLP-1R activationpromotes the secretion of atrial natriuretic peptide and a
reduction of blood pressure [33].
As DPP-4 cleaves a wide variety of substrates, including
stromal cell-derived factor-1 (SDF-1) alpha, which stimu-
lates the bone marrow mobilization of endothelial progeni-
tor cells (EPC) and brain natriuretic peptide (1–32), which
is the active form [34], DPP-4 inhibition may repair endo-
thelial cells and improve the cardiac function, thus resulting
in an indirect improvement of the endothelial function.
Lipid metabolism
DPP-4 inhibitors reduced the serum levels of choles-
terol and triglycerides in mice and humans [28,35].
GLP-1 also decreased the lipid absorption in vivo [36].
Therefore, incretins may improve the endothelial function
by correcting the lipid metabolism. However, exendin-4
did not affect the levels of cholesterol and triglycerides
in mice [35].
Clinical data
Table 2 lists the effects of GLP-1 and GLP-1-related drugs
on the endothelial function. Although GLP-1 enhanced
the endothelium-dependent and -independent responses
to ACh and sodium nitroprusside (SNP) during infusion
of insuline, but not during infusion of saline in patients
with metabolic syndrome. Furthermore, no changes in the
vasodilator reactivity in response to ACh and SNP were
seen after GLP-1 was added to insulin and vitamin C or
after GLP-1(9–36) was given during hyperinsulinemia
[37]. Kelly et al. demonstrated that exendin-4 did not im-
prove the responses of peripheral arterial tonometry com-
pared to metformin in patients with impaired glucose
tolerance [38]. In addition, exendin-4 and liraglutide could
not improve the FMD responses in obese patients with
T2DM [39]. Surprisingly, sitagliptin and alogliptin actually
led to a deterioration in the FMD responses in patients
with T2DM [40]. Since the DPP-4 inhibitors inhibited
DPP-4 activity and increased the level of GLP-1, in
addition to lowering the glucose level, in this study, it is
clear that the DPP-4 inhibitors worked efficiently. The au-
thors suggested that GLP-1(9–36), a metabolite of GLP-1
cleaved by the DPP-4 inhibitor, was thought to be inactive,
but possessed a vasodilatory effect ex vivo which was me-
diated by NO [6]. However, sitagliptin, alogliptin and vil-
dagliptin also improved the endothelial function in other
studies. Therefore, it is hard to simply conclude whether
the discrepancy was due to the differences in the drugs or
the inhibition of GLP-1 (9–36).
On the other hand, nine studies previously reported
that the endothelial function was improved by using
GLP-1 and GLP-1-related drugs [37,41-48]. This effect is
still being debated, because all of these studies included
a small number (< 50) of patients, and almost all were
non-randomized trials. Therefore, a large-scaled randomized
Table 2 Clinical evaluation of endothelial function
Author Subjects n Endothelial function Medication Control Duration Result
Basu A et al. [41] T2DM 29 Strain-gauged plethysmography GLP-1 Placebo 240 min Improved
Kubota Y et al. [42] T2DM 40 FMD Sitagliptin None 12 w Improved
Nystrom T et al. [43] T2DM 12 FMD GLP-1 Saline 115 min Improved
Koska J et al. [44] T2DM 28 PAT Exendin-4 Saline 210 min Improved
Noda Y et al. [45] Healty volunteer 10 FMD Alogliptin Placebo 1 w Improved
van Poppel PC et al. [46] T2DM 16 Strain-gauged plethysmography Vildagliptin Acarbose 4 w Improved
Ceriello A et al. [47] T2DM 28 FMD GLP-1 Saline 2 h Improved
Irace C et al. [48] T2DM 20 FMD Exendin-4 Glimepiride 16w Improved
Tesauro M et al. [37] Metabolic syndrome 10 (5/5) Strain-gauged plethysmography GLP-1 Saline 30 min Improved (conditional)
Kelly AS et al. [38] IGT 50 PAT Exendin-4 Metformin 6 m No change
Hopkins ND, et al. [39] Obese T2DM 11 FMD Exendin-4 (n = 9) Liragrutide (n = 2) None 6 m No change
Ayaori M et al. [40] T2DM 13 ~ 20,22 FMD Sitagliptin/alogliptin Voglibose 6 w Worsened
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agents on the endothelial function.
We designed and are performing an ongoing multicen-
ter randomized prospective study to evaluate the effects of
DPP-4 inhibition on carotid atherosclerosis by measuring
the carotid intima-media thickness (PROLOGUE trial:
UMIN000004490). In this trial, the effects of a DPP-4 in-
hibitor on the FMD will be analyzed as part of a subgroup
of the study. The result of this study may answer the ques-
tions remaining regarding the effects of DDP-4 inhibition.
Do incretins improve the prognosis and mortality from
cardiovascular disease?
Recently, the results of cardiovascular safety trials of type
2 diabetes drugs, EXAMINE trial with alogliptin and
SAVOR-TIMI 53 trial with saxagliptin, were reported
[49,50]. These two studies found no effect on the risk of
fatal or non-fatal cardiac events and no increases in the
risk of pancreatitis or pancreatic cancer. The results
were disappointing because the studies did not demon-
strate any cardiovascular protective benefits of DPP-4
inhibitors. There are a few limitations. First, the follow-
up period was too short to evaluate the incidence of car-
diovascular events, because the effects of drugs in fighting
pro-atherosclerotic processes in patients with T2DM re-
quires more than 10 years. Second, the relatively small
HbA1c-lowering effects of saxagliptin and alogliptin ob-
served in both trials, averaging only 0.3 to 0.4 percentage
points. It may influence the final results. Further sub-
analyses and other ongoing trials need to be waited.
We need to admonish against jumping illogically.
Additional features and limitations
The blood vessels modulate vascular tone and blood flow
by constricting or relaxing in response to physical, neuro-
logical and chemical stimuli. Endothelial dysfunction is
recognized as a major factor in the development of ath-
erosclerosis and FMD is designated as an endothelium-
dependent process that reflects the relaxation of a conduit
artery (brachial, radial, and femoral) when exposed to in-
creased blood flow and shear stress and recognized as use-
ful tool for the assessment of endothelial function in
different clinical and research populations. Recently FMD
is recognized as an independent predictor of future car-
diac events [51,52].
It is a simple and widely available method, however, there
are several caveats due to the potential technical variations
[53], these include:
1) An acceptable reproducibility is a mean difference
of 2% to 3% in the FMD over time. To measure the
FMD precisely, 100 independent supervised scans and
measurements are required according to a previous
report.2) At least 40 to 60 patients in a parallel-group study are
needed because of the fluctuation of the data.
3) The diameters of small arteries at baseline appear to
dilate more than those of larger arteries, and
repeated measurements of the diameter at baseline
must be the same. Therefore, the precise vessel
diameters before and after reactive hyperemia
(mean baseline and peak deflation diameters) have
to be addressed in addition to the % changes of
the FMD.
4) In multicenter studies, the methods used for the
measurement should be unified, and a core laboratory
should be used to analyze the FMD data to minimize
the variations among the different centers.
Measurement errors are present in all of the data be-
cause of the biological variations and methodological limi-
tations described above. Therefore, the evaluations must
be performed carefully and precisely. Guidelines for meas-
uring the FMD have been published [53-55], and the Japa-
nese Circulation Society will announce new guidelines in
2014. Therefore, it is necessary to recognize the limita-
tions and the features of FMD and to measure the FMD
as precisely as possible in compliance with the guidelines.
In addition to atherosclerosis, incretins may prevent
myocardial ischemia-reperfusion (I/R) injury. Sitagliptin
or vildagliptin for two weeks reduced infarct size after
myocardial I/R injury through the GLP-1 receptor-PKA
pathway, in a glucose-dependent manner in rat in
ex vivo [56] In addition, exendin-4 could attenuate myo-
cardial I/R injury which may be associated with inhibit-
ing the expression of high mobility group box 1 in ra
in vivo [57]. As myocardial ischemia-reperfusion is crit-
ical for the patients with coronary artery disease or acute
coronary syndrome who underwent percutaneous coron-
ary intervention, incretin-therapy may have beneficial ef-
fects beyond glycemic control.
Finally, we would like to add that this review is not a
systematic review or meta-analysis based on the PRISMA
guidelines [58].
Conclusions
Atherosclerosis and the subsequent cardiovascular dis-
ease are fatal, and early prevention of cardiovascular
complications by ensuring strict glucose control is essen-
tial for patients with T2DM. The current findings add to
a growing body of evidence that suggests that we might
be entering a new era of cardiovascular diabetology with
new anti-diabetic drugs for now. On the other hand,
several investigations contradicted the beneficial effects
of incretin on the vasculature. Therefore, as a next step,
large-scaled randomized, prospective, clinical studies
and their subanalyses will provide the evidence whether
incretin therapy provide clinical benefits of vascular
Oyama et al. Cardiovascular Diabetology 2014, 13:21 Page 7 of 8
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T2DM who are at risk of cardiovascular disease.
Abbreviation
T2DM: Type 2 diabetes mellitus; GLP-1: Glucagon-like peptide-1;
GIP: Insulinotropic polypeptide; GLP-1R: GLP-1 receptor; DPP: Dipeptidyl
peptidase; CVD: Cardiovascular disease; NO: Nitric oxide; FMD: Flow-mediated
dilation; ROS: Reactive oxygen species; AGE: Advanced glycation end
product; VCAM: Vascular cell adhesion molecule; HUVEC: Human umbilical
vein endothelial cells; eNOS: Endothelial NO synthase; VEGF: Vascular
endothelial growth factor; ICAM: Intercellular adhesion molecule; RAGE: The
receptor for AGE; ApoE-/-: apolipoprotein E deficient; SDF: Stromal cell-
derived factor; ACh: Acetylcholine; SNP: Sodium nitroprusside.
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